Back

A naturally randomized trial evaluating the potential clinical benefit of therapies that reduce triglyceride-rich lipoproteins on the risk of coronary heart disease

28 August 2018 (15:18 - 15:26)
Organised by:
Congress Presentation Part of: Late Breaking Registry Results 2 Drug therapy ESC Premium Access ESC Congress 2018

About the speaker

Photo
Professor Brian A Ference

University of Cambridge, Cambridge (United Kingdom of Great Britain & Northern Ireland)

12 More presentations in this session

Presentation thumbnail
Panel Discussants.
Video
Presentation thumbnail
GARFIELD-AF prospective registry - Comparative effectiveness of oral anticoagulants in everyday practice
Professor J. Camm (London, GB)
Slides Video
Presentation thumbnail
Panel discussion.
Video
Presentation thumbnail
GARFIELD-AF prospective registry - Adverse one-year outcomes for patients newly treated with oral anticoagulants plus antiplatelet therapy after a diagnosis of atrial fibrillation
Professor K. Fox (Edinburgh, GB)
Slides Video
Presentation thumbnail
Panel discussion.

Access the full session

Session thumbnail
Late Breaking Registry Results 2

The Event

Event poster

ESC Congress 2018

28 August 2018 15:18 CET
You may be interested in
thumbnail
Congress Presentation
Triglyceride lowering after MI
1 September 2025
thumbnail
Congress Presentation
REDUCE-IT: outcomes by baseline statin type
28 August 2020
thumbnail
Congress Presentation
From genes to trials in China: Lp(a) and ANGPTL3/4/8 as emerging atherosclerotic cardiovascular disease targets beyond LDL-C and inflammation?
29 August 2025
thumbnail
Congress Presentation
Baseline triglycerides and non-HDL-C and apoB goal attainment in the ORION-10 and ORION-11 trials
30 August 2020

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources